Radioligand peptide precursors
Chelator-conjugated peptides and small-molecule ligands prepared for radiolabeling with therapeutic or diagnostic isotopes. DOTA, NOTA, and NODAGA handles with GMP-minded analytics support theranostic oncology programs.
DOTA / NOTA
chelator families
177Lu / 68Ga
common isotope pairs
≥95%
peptide purity typical
Metal-free
chelator prep emphasis
Cold precursor supply
Radioligand therapy depends on a well-characterized cold precursor: the peptide or small molecule must bind the target, present a chelator with reproducible radiometal coordination kinetics, and remain stable until radiolabeling at the pharmacy or nuclear medicine site.
We manufacture precursors without isotope, with metal control and endotoxin awareness when paths lead to injectable drug product.
Precursor architecture
- 01
Binding domain
DOTA and NOTA peptide precursors for radioligand programs, with chelator matching and cold-precursor analytics.
- 02
Chelator
DOTA, NOTA, or NODAGA macrocycle, attached via side chain or N-terminal position, tuned for thermodynamic and kinetic stability with chosen metal.
- 03
Modulation spacer
Amino acid or PEG spacer sets distance between pharmacophore and metal, affecting receptor affinity and internalization.
Chelator and isotope pairing
Half-lives are isotope physical half-lives. Clinical scheduling and pharmacy handling follow local regulation.
| Isotope | Half-life (approx.) | Chelator fit | Typical role |
|---|---|---|---|
| ⁶⁸Ga | 68 min | NOTA, NODAGA (fast complexation) | PET imaging; same-day preparation |
| ¹⁸F | 110 min | Prosthetic approach or AlF-NOTA | PET; non-metallic labeling paths |
| ¹⁷⁷Lu | 6.7 d | DOTA, chelator rated for lutetium | Theranostic therapy; hospital inpatient logistics |
| ²²⁵Ac | 9.9 d | DOTA or engineered macrocycles | Alpha therapy; stringent radiochemical purity downstream |
| ⁹⁰Y | 64 h | DOTA | Beta therapy; dosimetry planning required |
| ⁶⁴Cu | 12.7 h | DOTA, NOTA | PET and therapy research; stability monitoring critical |
Pairing guidance is indicative for precursor design. Radiolabeling validation remains at the radiopharmacy with licensed methods.
Typical cold precursor release
Peptide purity
≥ 95% (often ≥ 98%)
RP-HPLC
Identity
HRMS + peptide map
Chelator attachment site
Metal residues
ICP-MS screening
As low as practical pre-radiolabel
Water
KF
Lyophilized presentation common
Endotoxin
LAL
When clinical injectable path
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
Handoff to radiolabeling site
Precursor release
COA with storage at −20 °C or lyophilized vials under inert atmosphere where specified.
Method transfer
Optional sharing of HPLC methods for radiochemical purity correlation.
Stability
Accelerated studies on cold material inform shipping windows; radiolabeled stability is pharmacy-validated.
Frequently asked questions
We supply cold precursors. Radiolabeling occurs at licensed nuclear pharmacies or hospital radiopharmacies.
Related
Peptide-Drug Conjugates
Tumor-homing peptides conjugated to cytotoxic or targeted payloads through cleavable or stable linkers. We synthesize and characterize peptide vectors, payloads, and assembled PDCs with potency-appropriate containment.
View detailsPeptide Modifications
Terminal caps, cyclization, stapling, PTMs, fluorescent and affinity tags, PEG/lipid appendages and unnatural backbones—installed during SPPS or in solution after the chain is built. Each class changes synthesis time, purification and how the product should be specified on the COA.
View detailsCustom Peptide Synthesis
Solid-phase and solution synthesis of linear and modified peptides for discovery, assay development and lead optimization. Scale, purity tier and QC depth are matched to how the material will be used—not every program needs the same finishing step.
View detailsDiagnostic & Device Peptides
Highly controlled peptides for immunoassays, biosensors, calibration curves and device coatings—where lot-to-lot consistency, label integrity and low host-interference matter more than gram-scale bulk.
View detailsReady to specify this for your program?
Share sequence, scale and documentation needs. We reply with indicative specs and a project-specific quotation.